Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of guadecitabine versus treatment choice in untreated AML patients unfit for intensive induction chemotherapy
2014-001233-89Phase 3Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Mar 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of guadecitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Astex Pharmaceuticals. Primary endpoints: Complete response rate and Overall survival. Started Mar 2015; status: completed.
02
Drugs
guadecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2014-001233-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001233-89.